Skip to content

Flying below the radar on August 22nd: Two growth stocks about to take off

Flying below the radar: 2 growth stocks about to take off
Kliment Dukovski

Investing in growth stocks can be an extremely profitable strategy if you buy in early. However, this also comes with a high risk that the investment may not pay off.

Finbold analyzed on August 22 the best stocks in terms of growth potential and selected the two that came on top.

Taysha Gene Therapies (NASDAQ: TSHA)

Taysha Gene Therapies is a patient-centric gene therapy company. It develops and commercializes adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.

The company recently made progress in advancing its gene therapy, known as TSHA-102, for the treatment of patients with Rett Syndrome. It also has another promising gene therapy candidate — TSHA-120. This treatment is for patients with Giant Axonal Neuropathy.

Taysha has enough cash and cash equivalents to fund its operations into Q3 of 2025, according to its SEC filing, which means it’s unlikely that the company will need to raise funds soon and dilute current holders.

Even more promising is the fact that four insiders bought a combined 17 million shares in August worth $15 million total.

Insider trading. Source:

Five analysts at TipRanks have rated this stock as ‘strong buy’ with a price target of $6 in the next 12 months. That’s 212% higher than the current price of $1.92.

TipRanks analyst consensus. Source: Interactive Brokers Fundamentals Explorer

Xponential Fitness (NYSE: XPOF)

Xponential Fitness is a holding company that is a global franchisor of boutique fitness brands via its subsidiaries. This includes ten brands spread across pilates, indoor cycling, stretching, rowing, dancing, boxing and more.

The company has seen a sales growth of more than 20% over the previous two quarters. Membership also grew 31% in North America to 665,000. In the previous quarter, the company opened 115 new studios, bringing it to a total of 2,765 studios worldwide.

TipRanks analysts have placed a ‘strong buy’ rating based on 12 analysts in the past three months. Their price target for the next 12 months is $34.91, or 62% higher than the current price of $21.48.

TipRanks analyst consensus. Source: Interactive Brokers Fundamentals Explorer

Five insiders bought a total of 59,340 shares in August worth around $1.4 million. This is often a bullish signal when company executives buy shares. 

TipRanks analyst consensus. Source: Interactive Brokers Fundamentals Explorer

Finally, Xponential Fitness is down 5% year-to-date, while Taysha Gene Therapies is down 12%. Both have been outperformed by the S&P 500’s 15% return during the same period.

Buy stocks now with Interactive Brokers – the most advanced investment platform

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in 70+ cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. eToro USA LLC does not offer CFDs, only real Crypto assets available. Don’t invest unless you’re prepared to lose all the money you invest.

Read Next:

Weekly Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.